Free Trial

InflaRx Q2 2024 Earnings Report

InflaRx logo
$2.51 +0.01 (+0.40%)
(As of 01:48 PM ET)

InflaRx EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.21
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

InflaRx Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.04 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

InflaRx Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

After New Years, price goes back up 4,800% (Ad)

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

InflaRx Earnings Headlines

InflaRx's (IFRX) Buy Rating Reiterated at HC Wainwright
InflaRx announces first patient dosed in 2a study of CSU, HS
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug
InflaRx initiated with a Buy at Lucid Capital
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

View InflaRx Profile

More Earnings Resources from MarketBeat